IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US
Condition: COPD Interventions: Drug: Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.; Other: External Comparator Sponsors: AstraZeneca; Iqvia Pty Ltd; Premier Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere ™ in Routine Care Settings in Greece
Condition: Pulmonary Disease, Chronic Obstructive (COPD) Intervention: Combination Product: Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
